Quarterly results
We announce our results on a quarterly basis.
This section contains details of our results announcements, to view and download, along with links to related webcasts and presentations. Results from previous years are archived by date, and can be accessed via the filter below.
Refine by year: You can select a specific year to look at all four quarters of results.
2013 First Quarter - released on 24 April 2013
Key highlights
- Core EPS of 26.9p and dividend of 18p
- Group sales -2% reflecting continued contribution from key growth drivers offset by expected demanding prior year comparisons
- Continued R&D pipeline progress
- Continued delivery of financial efficiencies, strong cash generation and returns to shareholders
- Further measures to drive strategic focus and improve growth profile
- 2013 expectations for sales growth (~1%) and core EPS growth (3-4%) unchanged (both at CER)
2012 Fourth Quarter - released on 6 February 2013
"In 2012, despite a challenging operating environment, we have maintained core earnings per share on a CER basis, returned over £6.3 billion to shareholders and made outstanding progress to advance potential new medicines across multiple disease areas."
Sir Andrew Witty, CEO
Key highlights
- Core EPS of 112.7p and returns of £6.3bn to shareholders
- 2012 dividend of 74p (+6%)
- Group sales -1%; flat excluding disposals of OTC brands
- Successful R&D delivery: six new drugs filed since start of 2012
2012 Third Quarter - released on 31 October 2012
Key highlights
- Core EPS of 26.5p
- Dividend of 18p (+ 6%)
- Further successful R&D delivery: phase III programmes completed for 6 novel medicines in 2012
- Continued strong cash generation and returns to shareholders
2012 Second Quarter - released on 25 July 2012
"The very significant progress made in our late-stage pipeline provides us with increasing confidence that we have the ability to deliver long-term sustainable sales growth and improving returns to shareholders."
Sir Andrew Witty, CEO
Key highlights
- Core EPS of 26.4p
- Dividend of 17p (up 6%)
- Significant late-stage pipeline delivery
2012 First Quarter - released on 25 April 2012
Key highlights
- Sales growth of +2% CER
- Further R&D delivery, operational leverage and continued returns to shareholders
- Core EPS 27.3p (+7%), dividend up 6% to 17p
2011 Fourth Quarter - released on 7 February 2012
"Three and a half years ago, we set out to fundamentally change GSK to create a more balanced business capable of addressing the market challenges we face, delivering sustainable financial performance and providing new value to patients and consumers. Our record in 2011 demonstrates that we are succeeding."
Sir Andrew Witty, CEO
Key highlights
- 2011 underlying sales +4% (reported -3%)
- EPS before major restructuring* 114.1p
- Total dividends of 75p
2011 Third Quarter - released on 26 October 2011
Key highlights
- Underlying sales growth of 6% and reported sales growth of 3%
- EPS before major restructuring 28.5p, dividend 17p (up 6%)
- Strong contribution from Japan: sales +57%
2011 Second Quarter - released on 26 July 2011
"We have had a strong second quarter, with continued underlying sales growth, new product delivery, pipeline visibility and cash generation. This progress is very much in line with our expectations and it is clear that our strategy is delivering."
Andrew Witty, CEO
Key highlights
- Q2 reported sales -2%
- EPS before major restructuring* 25p
- Underlying sales growth of 5%
- Increased pipeline visibility and dividend of 16p, up 7%
2011 First Quarter - released on 27 April 2011
Key highlights
- Reported sales -10%, underlying sales +4%
- EPS before major restructuring 32.2p (+9%), dividend 16p (+7%)
2010 Fourth Quarter - released on 3 February 2011
"We have substantially re-engineered GSK’s business model over the last two and a half years, through major restructuring and a rigorous returns-based approach to capital allocation."
Andrew Witty, CEO
Key highlights
- Long-term share buy-back programme initiated
- 2010 dividend up 7% to 65p
2010 Third Quarter - released on 21 October 2010
Key highlights
- Q3 EPS before major restructuring of 28.2p
- Q3 dividend up 7% to 16p
2010 Second Quarter - released on 21 July 2010
"We are making good progress to build our group of healthcare businesses which offer sustainable growth and have complementary risk/value profiles. At the same time, we have also taken action to drive improved returns on invested capital in our core R&D operation."
Andrew Witty, CEO
Key highlights
- Q2 EPS before major restructuring 2.6p (29.3p excluding pre-announced legal charge)
- Q2 dividend increased 7% to 15p
2010 First Quarter - released on 28 April 2010
Key highlights
- Q1 sales £7.4bn up 13% CER
- Underlying sales (excluding pandemic products) up 4% CER
2009 Fourth Quarter - released on 4 February 2010
"Our strategy is delivering and I believe that GSK is now moving to a position where we can deliver our goal of long-term sustainable financial performance. 2009 saw GSK return to sales growth and I am confident of our prospects in 2010."
Andrew Witty, CEO
Key highlights
- Strategy supports return to sales growth (+3%)
- Sustained R&D productivity; with further actions to improve returns
2009 Third Quarter - released on 29 October 2009
Key highlights
- Return to sales growth with Q3 turnover +3% CER; +15% sterling
- Continued improvement expected in Q4
2009 Second Quarter - released on 22 July 2009
"Today’s results indicate a marked improvement on the first quarter and I expect this to continue in the second half of 2009 as the year-on-year comparative effect of US generic competition reduces and we see further sales contributions from new products and our influenza portfolio."
Sir Andrew Witty, CEO
Key highlights
- Improving performance to continue in second half of 2009
- Good progress made to deliver strategic priorities
2009 First Quarter - released on 22 April 2009
Key highlights
- GSK delivers Q1 EPS of 26.3p before major restructuring*
- Increased dividend of 14p